Clonal chromosomal abnormalities in CD34+/CD38− hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic …
T Bumm, J Deininger, AH Newell, H Lawce, S Olson… - Leukemia, 2010 - nature.com
T Bumm, J Deininger, AH Newell, H Lawce, S Olson, M Mauro, B Druker, M Deininger
Leukemia, 2010•nature.comLymphoid Tissues, 4th edn. IARC Press: Lyon, 2008. 2 Stone RM, DeAngelo DJ, Klimek V,
Galinsky I, Estey E, Nimer SD et al. Patients with acute myeloid leukemia and an activating
mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.
Blood 2005; 105: 54–60. 3 Knapper S, Burnett AK, Littlewood T, Kell WJ, Agrawal S, Chopra
R et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for
older patients with acute myeloid leukemia not considered fit for intensive chemotherapy …
Galinsky I, Estey E, Nimer SD et al. Patients with acute myeloid leukemia and an activating
mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.
Blood 2005; 105: 54–60. 3 Knapper S, Burnett AK, Littlewood T, Kell WJ, Agrawal S, Chopra
R et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for
older patients with acute myeloid leukemia not considered fit for intensive chemotherapy …
Lymphoid Tissues, 4th edn. IARC Press: Lyon, 2008. 2 Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005; 105: 54–60. 3 Knapper S, Burnett AK, Littlewood T, Kell WJ, Agrawal S, Chopra R et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006; 108: 3262–3270.
nature.com